Goal
Regenerate new hair follicles to treat baldness and other hair-loss conditions
Problem
Androgenetic alopecia (male-pattern baldness) and other follicle-degeneration disorders
Concept Summary
The technology uses a minimally invasive skin-perturbation device to remove the superficial epidermal layers, triggering dedifferentiation of skin cells into a stem-like state. A topical formulation containing molecular agents (e.g., EGFR inhibitors, FGF9, Wnt proteins, retinoids, anti-androgens) is then applied to direct these cells to form de-novo hair follicles. Pre-clinical mouse studies and early human trials report consistent follicle neogenesis and significant increases in follicle numbers when key pathways such as Wnt or FGF9 are modulated.
Principles
- Wound-healing induced epidermal dedifferentiation
- Modulation of Wnt signaling
- Application of fibroblast growth factor-9 (Fgf9)
- EGFR pathway inhibition
- Topical delivery of growth-factor cocktails
Scientific Domains
Materials
- Small-molecule EGFR inhibitors (e.g., leflunomide, gefitinib, erlotinib, lapatinib)
- EGFR antibodies (e.g., cetuximab, zalutumumab)
- Recombinant FGF9 polypeptide
- Wnt ligands or agonists
- Retinoids (e.g., 13-cis-retinoic acid, all-trans-retinoic acid)
- Anti-androgens (e.g., finasteride, dutasteride, RU58841)
- Minoxidil (channel opener)
- Anti-inflammatory corticosteroids
- Antihistamines (e.g., diphenhydramine)
Mechanisms of Action
- Mechanical disruption of epidermis creates a transient stem-cell-like state
- Topical agents activate signaling pathways (Wnt, Fgf9, EGFR) that drive follicle lineage commitment
- Inhibition of EGFR promotes differentiation toward hair-follicle fate
Applications
- Treatment of androgenetic alopecia
- Regeneration of hair follicles after scarring
- General skin regeneration therapies
Claimed Performance
Pre-clinical mouse studies show up to a 23-fold increase in follicle formation with Fgf9 over-expression; early human trials report consistent creation of new follicles after device treatment and topical application.
Experimental Evidence
Nature 2007 (Wnt modulation) and Nature Medicine 2013 (Fgf9) studies in mice; Follica's own pre-clinical and early-phase clinical trials (as reported in The Scientist article).
Replication Status
Pre-clinical mouse data published; early human trial data reported by Follica; no independent third-party replication documented.
Limitations
- Requires controlled epidermal disruption (potential for scarring)
- Long-term safety of repeated skin perturbation not yet known
- Regulatory approval pending for many of the topical agents
